CASC2 and cervical carcinoma: Mechanistic studies have shown that CASC2 can competitively inhibit miR-21, thereby increasing the miR-21 expression of the downstream target protein PTEN (tumor suppressor), and PTEN can increase the chemosensitivity of cervical cancer cells to cisplatin by regulating the AKT signaling pathway [32] (Fig. 1k).